Ibrance
What Ibrance is used for
Ibrance is indicated for the treatment of hormone receptor (HR) positive, human epidermal growth factor receptor 2 (HER2) negative locally advanced or metastatic breast cancer: in combination with an aromatase inhibitor; in combination with fulvestrant in women who have received prior endocrine therapy. In pre- or perimenopausal women, the endocrine therapy should be combined with a luteinizing hormone releasing hormone (LHRH) agonist.
Approved use, as published by the European Medicines Agency.
Key facts
- Brand
- Ibrance
- Active substance
- palbociclib
- Disease area
- Breast Neoplasms
- Medicine group
- Antineoplastic agents
- ATC code
- L01EF01
- Marketing authorisation holder
- Pfizer Europe MA EEIG
- Authorised in the EU since
- 2016
Official information
In the USA
Same active substance: Ibrance
In India
- Palbociclib: 4 brands in India
Specialist medicine: started and supervised by a specialist doctor or hospital. This page is a plain-language summary of public official information, not medical advice; follow your doctor and the official product information.
Common questions
What is Ibrance used for?
Ibrance is indicated for the treatment of hormone receptor (HR) positive, human epidermal growth factor receptor 2 (HER2) negative locally advanced or metastatic breast cancer: in combination with an aromatase inhibitor; in combination with fulvestrant in women who have received prior endocrine therapy. In pre- or perimenopausal women, the endocrine therapy should be combined with a luteinizing hormone releasing hormone (LHRH) agonist.
What is the active substance in Ibrance?
Ibrance contains palbociclib.
Who makes Ibrance?
The EU marketing authorisation holder is Pfizer Europe MA EEIG.
Source: European Medicines Agency medicines data (ema.europa.eu), reproduced with acknowledgement of the source. Page made 5 November 2026 by Satya Babu.
← All specialty medicines, EU